- Home
- COYA
as 07-26-2024 4:00pm EST
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 92.1M | IPO Year: | 2022 |
| Target Price: | $16.00 | AVG Volume (30 days): | 42.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.21 - $10.69 | Next Earning Date: | 08-06-2024 |
| Revenue: | $6,129,044 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -13.33% | Revenue Growth (next year): | 32.35% |
Stock Insider Trading Activity of Coya Therapeutics Inc. (COYA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lee Ann | COYA | Director | Aug 22 '23 | Buy | $3.62 | 1,000 | $3,620.00 | 17,479 | SEC Form 4 |
Latest Coya Therapeutics Inc. News
COYA Breaking Stock News: Dive into COYA Ticker-Specific Updates for Smart Investing
Business Wire
a month ago
Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic
Business Wire
2 months ago
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
Business Wire
2 months ago
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
Business Wire
2 months ago
Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index
Benzinga
2 months ago
EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases
Clinical Trials Arena
2 months ago
Coya Therapeutics concludes Phase II Alzheimer’s therapy trial
Business Wire
2 months ago
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
MT Newswires
2 months ago
Coya Therapeutics Receives $5 Million Equity Investment from Alzheimer's Drug Discovery Foundation
Compare COYA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "COYA Coya Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.